A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

NCT05883956 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Chronic
Patient Preference

Interventions

DRUG: Subcutaneous azacitidine
DRUG: Oral decitabine/cedazuridine

Sponsor

Otsuka Australia Pharmaceutical Pty Ltd